Recombinant Human Beta-2-glycoprotein 1 (APOH)

Uniprot Id

P02749

Target Species

Human

Target Name

APOH

Target Full Name

Beta-2-glycoprotein 1

Target Function

Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells.

Target Subcellular Location

Secreted.

Target Tissue Specificity

Expressed by the liver and secreted in plasma.

Target Synonyms

Activated protein C binding protein; Activated protein C-binding protein; Anticardiolipin cofactor; APC inhibitor; Apo-H; APOH; APOH_HUMAN; apolipoprotein H (beta-2-glycoprotein I); Apolipoprotein H; B2G1; B2GP1; B2GPI; Beta 2 glycoprotein I; Beta 2 glycoprotein I precursor; Beta(2)GPI; Beta-2-glycoprotein 1; Beta-2-glycoprotein I; BG; Glycoprotein 1; beta-2; Glycoprotein I; beta-2; OTTMUSP00000003033

Target Background

Apolipoprotein H, also known as beta-2-glycoprotein I, is a component of circulating plasma lipoproteins. It has been implicated in a variety of physiologic pathways including lipoprotein metabolism, coagulation, hemostasis, and the production of antiphospholipid autoantibodies. APOH may be a required cofactor for anionic phospholipid binding by the antiphospholipid autoantibodies found in sera of many patients with lupus and primary antiphospholipid syndrome (APS). The anti-beta (2) glycoprotein I antibodies from APS patients, mediate inhibition of activated protein C which has anticoagulant properties. Because beta-2-GPI is the main autoantigen in patients with APS, the disruption of this pathway by autoantibodies may be an important mechanism for thrombosis in patients with APS.